Probiotic BSA-5.1 based on Akkermansia metabolic disorders corrector 60 capsules

Probiotic BSA-5.1 is an innovative product containing Akkermansia muciniphila. It modulates intestinal permeability and strengthens intestinal barrier function. It helps prevent metabolic disorders. It may improve dyslipidemia, hyperglycemia, atherosclerosis, and liver problems.

BSA-5.1 is an innovative probiotic containing the bacterium Akkermansia muciniphila and prebiotic galactooligosaccharides.

Akkermansia muciniphila is a species of mucin-degrading bacteria that is part of the natural human microbiome. It has clinically proven efficacy and is safe for use as a probiotic.

Akkermansia muciniphila has a number of beneficial properties. It improves metabolic pathways associated with lipid metabolism and is effective in preventing dyslipidemia. May increase triglyceride and postprandial chylomicron clearance, which helps reduce their levels, prevent acute lipid overload, and thereby improve conditions such as vascular atherosclerosis and heart failure. It has an anti-inflammatory effect on the circulatory system as a whole and local atherosclerotic lesions. It helps reduce macrophage infiltration and the expression of proinflammatory cytokines and chemokines.
Enhances intestinal barrier function. Modulates intestinal permeability by increasing the expression of tight junction proteins in intestinal epithelial cells (occludin, claudin 3, cannabinoid receptor 1). It attenuates metabolic endotoxemia by reducing circulating endotoxin levels. It has an anti-inflammatory effect in chronic colitis, reducing the production of proinflammatory cytokines in the colon, including TNF-α and IFN-γ. Akkermansia muciniphila also helps protect liver cells from alcohol-induced damage, neutrophil infiltration, and steatosis. It reduces blood markers associated with dysfunction and inflammation. It may help with fatty liver disease, liver inflammation, and hypercholesterolemia.
By producing short-chain fatty acids through the conversion of dietary fiber to acetate, propionate, and butyrate, Akkermansia muciniphila positively influences glucose and lipid homeostasis. It increases insulin sensitivity, reduces hyperinsulinemia and cholesterol, and promotes weight loss.

Another active ingredient, galactooligosaccharides, are prebiotics that create favorable conditions for the growth of beneficial bacteria.
Galactooligosaccharides inhibit the binding or survival of Escherichia coli, Salmonella, and Clostridia. They can positively influence the immune system by stimulating the production of bacteriocins – specific proteins that suppress the proliferation of pathogenic bacteria.

The probiotic BSA-5.1 provides metabolic correction in obesity, dyslipidemia, metabolic syndrome, insulin resistance, and type 2 diabetes. Since the amount of Akkermansia muciniphila in the colon microbiome decreases with age, it is especially recommended for older adults to support metabolism and overall health in age-related diseases.

Contraindications: individual intolerance to the components, foodborne illnesses, acute intestinal infections, children under 3 years of age, and antibiotic therapy.

Combination options for probiotics in the BS line are described in the article at the link.

Directions for use: 1 capsule after meals 2-3 times daily. It is recommended to take it in combination with BSR-1 as follows: 1 capsule of BSR-1 and 1 capsule of BSA-5.1 twice daily, after meals.

Composition: One enteric-coated capsule of hydroxypropyl methylcellulose contains:
Psyllium (Plantago psyllium, 225 mg);
Akkermansia muciniphila (at least 2.5 x 109 CFU);
Galactooligosaccharides 250 mg.

Packaging: glass bottle.